Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy
| Autor: | Masahiko Nakao, Yuuki Kogure, Yohei Kawasaki, Kenichi Suzuki, Keita Hirai, Kazuyuki Inoue, Makoto Nishio, H. Ayuhara, Daiki Tsuji, Mari Yokoi, Koji Takeda, Kunihiko Itoh, Toshihiro Hama, Toshinobu Hayashi, Kazuhiko Shibata |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Vomiting Nausea medicine.drug_class Granisetron Logistic regression Polymorphism Single Nucleotide Dexamethasone 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Antiemetic Genetic Predisposition to Disease Aprepitant Aged Randomized Controlled Trials as Topic business.industry Odds ratio Middle Aged Palonosetron 030104 developmental biology Clinical Trials Phase III as Topic 030220 oncology & carcinogenesis Antiemetics Female Cisplatin medicine.symptom business medicine.drug Chemotherapy-induced nausea and vomiting |
| Zdroj: | Supportive Care in Cancer. |
| ISSN: | 1433-7339 0941-4355 |
| Popis: | Younger age and female sex have already been well-known risk factors for chemotherapy-induced nausea and vomiting (CINV), and 30–50% of cancer patients still suffer from CINV. Genetic polymorphisms are suggested to influence antiemetic treatment response. This study included a subset of patients previously enrolled in a randomised controlled trial; 156 patients were evaluated. This study aimed to evaluate the role of pharmacogenomic polymorphisms relevant to antiemetic response in patients with cancer receiving cisplatin-based chemotherapy. The study’s efficacy endpoint was the proportion of patients with complete response (CR). The study endpoint was evaluated separately in the acute (CR0–24) and delayed (CR24–120) phases. Thirteen polymorphisms were genotyped, and the association of these genotypes with the efficacy of prophylactic antiemetics was then investigated. Confounding variables for the CR were identified using stepwise multivariate logistic regression analysis. Age and sex were included as independent variables by the forced-entry method, and the stepwise method was used to select the pharmacogenomic factors for inclusion as independent variables. Multivariate logistic regression analysis revealed that the ERCC1 8092AA (odds ratio [OR] = 11.25; 95% confidence interval [CI] 1.74–72.71; p = 0.011) and female sex (OR = 3.63; 95% CI 1.14–11.58; p = 0.029) were significant predictors of CR0–24. No significant association of CR24–120 with pharmacogenomic polymorphisms was found via multivariate logistic regression analysis. ERCC1 polymorphism influenced the extent of CINV control in patients receiving cisplatin-based chemotherapy. Clinical trial information: UMIN 000009335 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink